Hostname: page-component-8448b6f56d-xtgtn Total loading time: 0 Render date: 2024-04-19T13:23:41.229Z Has data issue: false hasContentIssue false
  • English
  • Français

Chronic Levodopa and Renal Function

Published online by Cambridge University Press:  18 September 2015

Margaret M. Hoehn
Margaret M. Hoehn*
Affiliation:
University of Colorado Health Sciences Center, Denver, Colorado
*
Box A035, University of Colorado Medical Center, 4200 East 9th Avenue, Denver, Colorado, USA, 80262
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Renal function studies were performed in seventeen patients, under metabolic ward conditions, before the initiation of therapy with levodopa. These studies were repeated during the first two to three weeks of treatment and, again, after one to two years of chronic therapy. There were no significant differences between the results of pre- and post-therapy studies, except that the blood urea nitrogen was slightly, but significantly, elevated in the nine patients who had been on the drug for one to two years. During the early weeks of treatment, there was an insignificant trend towards hypotension and increased excretion of sodium. This did not persist in those patients followed for one to two years after the initiation of treatment. Glomerular filtration rate, as measured by an endogenous method, was unchanged by chronic therapy with levodopa. These results are in contrast to the acutely increased glomerular filtration rate, as measured by an exogenous method, and the increased sodium excretion following a single dose of levodopa or dopamine.

Type
Articles
Information
Canadian Journal of Neurological Sciences , Volume 8 , Issue 2 , May 1981 , pp. 139 - 142
Copyright
Copyright © Canadian Neurological Sciences Federation 1981

References

Barbeau, A., Gillo-Joffroy, L., Boucher, R., Nowaczynski, W., and Genest, J. (1969). Renin-aldosterone system in Parkinson’s disease. Science 165, 291–292.CrossRefGoogle ScholarPubMed
Bell, C., Lang, W.L. (1973). Neural dopaminergic vasodilator control in the kidney. Nature New Biol. 246, 27–29.CrossRefGoogle ScholarPubMed
Davis, B.B., Walter, M.J., and Murdaugh, H.V. (1968). The mechanism of the increase in sodium excretion following dopamine infusion. Proc. Soc. Exp. Biol. Med. 129, 210–213.CrossRefGoogle ScholarPubMed
Eble, J.N. (1964). A proposed mechanism for the depressor effect of dopamine in the anesthetized dog. J. Pharmacol. Exp. Ther. 145, 64–70.Google ScholarPubMed
Finlay, G.D., Whitsett, T.L., Cucinell, E.A., and Goldberg, L.I. (1970). Cardiac and renal effects of L-dopa in patients with Parkinson’s disease and congestive heart failure. Circulation 42 (Suppl. Ill), 109.Google Scholar
Finlay, G.D., Whitsett, T.L., Cucinell, E.A., and Goldberg, L.I. (1971). Augmentation of sodium and potassium excretion, glomerular filtration rate, and renal plasma flow by levodopa. New Eng. J. Med. 284, 865–870.CrossRefGoogle ScholarPubMed
Goldberg, L.I., Mcdonald, J.R., R.H., Zimmerman, A.M. (1963). Sodium diuresis produced by dopamine in patients with congestive heart failure. New Eng. J. Med. 269, 1060–1064.CrossRefGoogle ScholarPubMed
Goldberg, L.I. and Whitsett, T.L. (1971). Cardiovascular effects of levodopa. J. Amer. Med. Assoc. 218, 1921–1923.CrossRefGoogle ScholarPubMed
Katz, F.H. and Hoehn, M.M. (1977). Effects of levodopa on the renin-aldosterone system. Clin. Pharmacol. Therapeutics 21, 388–391.CrossRefGoogle ScholarPubMed
Keenan, R.E. (1970). The Eaton collaborative study of levodopa therapy in parkinsonism: a summary. Neurol. (Minneap.) 20, Part 2, 46–59.Google ScholarPubMed
Mcdonald, JR., R.H., Goldberg, L.I., Mcnay, J.L., and Tuttle, JR., E.P. (1964). Effects of dopamine in man: Augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J. Clin. Invest. 43, 1116–1124.CrossRefGoogle ScholarPubMed
Mcnay, J.L., McDonald, R.H. JR., and Goldberg, L.I. (1965). Direct renal vasodilation produced by dopamine in dogs. Circ. Res. 16, 510–517.CrossRefGoogle Scholar
Mcnay, J.L., McDonald, R.J. JR., and Goldberg, L.I. (1966). Comparison of the effects of dopamine, isoproterenol, norepinephrine, and bradykinin on canine renal and femoral blood flow after POB. J. Pharmacol. Exp. Ther. 151, 23–31.Google Scholar
Meyer, M.B., McNay, J.L., and Goldberg, L.l. (1967). Effects of dopamine on renal function and hemodynamics in the dog. J. Pharmacol. Exp. Ther. 156, 186–192.Google ScholarPubMed
Michelakis, A.M. and Robertson, D. (1970). Plasma renin activity and levodopa in Parkinson’s disease. J. Amer. Med. Assoc. 213. 83–85.CrossRefGoogle ScholarPubMed
Needleman, P., Douglas, J.R. Jr., Jakschik, B., Stolcklein, P.B., and Johnson, E.M. Jr. (1974). Release of renal prostaglandin by catecholamines: relationship to renal endocrine function. J. Pharmacol. Exp. Ther. 188, 453–460.Google ScholarPubMed
Rappelli, A., Glorioso, N., Tedde, R., Dessi’-Fulgheri, P., and Monaco, F. (1978). Effects of levodopa alone and in combination with dopadecarboxylase inhibitors on plasma renin activity in patients with Parkinson’s disease. J. Neurol. Neurosurg. Psychiat. 41, 915–918.CrossRefGoogle ScholarPubMed
Sullivan, J.M., Nakano, K.K., and Tyler, H.R. (1973). Plasma renin activity during levodopa therapy. J. Amer. Med. Assoc. 224, 1726–1729.CrossRefGoogle ScholarPubMed
Whitsett, T.L., Mckinney, A.S., and Goldberg, L.I. (1970). Tolerance to the cardiac effects of L-dopa in patients with Parkinson’s disease. Clin, Res. 18. 28.Google Scholar